Loading…
Loading…
000518.SZ does not currently pay a dividend.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for 000518.SZ and 80,000+ other tickers.
See exactly how 000518.SZ's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for 000518.SZ and 80,000+ other tickers.
Jiangsu Sihuan Bioengineering Co., Ltd. is a Chinese pharmaceutical company. Its product portfolio includes anti-cancer biotherapeutics such as Drewson, prescribed for renal cancer, malignant melanoma, and cancerous effusions in the chest and abdomen. Another significant oncology drug, Xinde Lusheng, targets a much wider spectrum of malignancies, including kidney, melanoma, lung, gastric, malignant lymphoma, breast, ovarian, bowel, bladder, head and neck tumors, and leukemia, in addition to cancerous pleural effusions. Beyond oncology, the company also produces Xin grain health, a recombinant…
No recent news available.